COMMUNIQUÉS West-GlobeNewswire

BioCryst Announces Departure of Dr. Helen Thackray
11/08/2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company [...]
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
11/08/2025
Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studies Trial initially taking place in the U.S., following IND clearance Initial data expected in mid-2026 from open-label Phase 1 [...]
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
11/08/2025
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed The company plans [...]
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
11/08/2025
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and [...]
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
11/08/2025
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe [...]
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
11/08/2025
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Part A testing every 3 [...]
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events
11/08/2025
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to [...]
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
11/08/2025
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
11/08/2025
Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA) DRAGON trial completion expected by Q4 2025 (including a three-month follow-up period) [...]
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
11/08/2025
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s disease 1 Ianalumab [...]
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
11/08/2025
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a [...]
Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025
11/08/2025
Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025 Mont-Saint-Guibert, Belgique – 11 août 2025, 7h00 CET / 01h00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), [...]
Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds
11/08/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 11, 2025 Idorsia Ltd (SIX: IDIA) announces the interim results of the repurchase offer for its outstanding CHF 204 * million convertible bonds [...]
AVITA Medical to Host Investor Webinar Briefing
11/08/2025
VALENCIA, Calif., Aug. 10, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective [...]
RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges
10/08/2025
Total Company Revenue increased 8.4% to a quarterly record of $498.2 million in the second quarter of 2025 from $459.7 million in the second quarter of 2024; Revenue from the Digital Health reportable segment (inclusive [...]
IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
10/08/2025
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 [...]
Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand
09/08/2025
Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Folqs, a U.S.-based wellness company, introduces new consumer product, Folqs First-Day Colostrum Powder . This positions the company within the growing colostrum [...]
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
09/08/2025
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE [...]
XORTX Completes USD $114,500 Private Placement
09/08/2025
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 08, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX [...]

Pages